Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Spina

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Immunotherapy|December 23, 2010
Immunotherapy targeting colon cancer stem cellsFlora Iovino, Serena Meraviglia, Marisa Spina, et al.
Cancers|November 12, 2013
Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease BreakdownSimone Di Franco, Pietro Mancuso, Antonina Benfante, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 16, 2010
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cellsMatilde D'Asaro, Carmela La Mendola, Diana Di Liberto, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Immunotherapy|December 23, 2010
Immunotherapy targeting colon cancer stem cellsFlora Iovino, Serena Meraviglia, Marisa Spina, et al.
Cancers|November 12, 2013
Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease BreakdownSimone Di Franco, Pietro Mancuso, Antonina Benfante, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 16, 2010
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cellsMatilde D'Asaro, Carmela La Mendola, Diana Di Liberto, et al.
Pageof 1